Nurtec ODT Dose Conversion: Weekly to Daily Rimegepant Explained

What "dose conversion" actually means with Nurtec ODT

The phrase "Nurtec ODT dose conversion" misleads some patients because rimegepant has only one tablet strength: 75 mg. The conversion is not about changing the milligram amount. It is about changing the schedule from as-needed acute use to every-other-day preventive use, both approved at the same 75 mg dose.

The FDA prescribing label for rimegepant states that for preventive treatment of episodic migraine in adults, the recommended dose is 75 mg every other day. No dose escalation period is required. You simply shift from "take one tablet when a migraine starts" to "take one tablet on Monday, skip Tuesday, take one tablet on Wednesday," and so on.

This matters clinically because some patients and even some prescribers think there is a slow weekly-to-daily titration, similar to older oral preventives like topiramate or amitriptyline. There is not. The tablet is the same. The pharmacokinetics are the same. Only the frequency changes.

Why the schedule looks "weekly" at first

Many clinicians initially prescribe rimegepant for acute use, which for a woman with two to four migraines per month may look like one or two tablets per week. When migraine frequency climbs above four headache days per month, or when acute medication use itself becomes a risk factor for medication-overuse headache, the conversation shifts to prevention. That jump from sporadic acute use to a fixed every-other-day schedule is what patients search for as a "weekly to daily conversion."

The every-other-day schedule is not "daily"

Every-other-day dosing gives approximately 15 tablets per 30-day period. True daily dosing (one tablet every 24 hours) is not FDA-approved for rimegepant. If you see a prescription written for one tablet daily, that is off-label. The approved preventive label is every other day, and the key trial used that schedule.

The trial behind every-other-day dosing: BHV3000-305

The evidence for every-other-day rimegepant as a preventive comes from the phase 3 BHV3000-305 randomized controlled trial published in The Lancet in 2021. The study enrolled 1,032 adults with four to 18 migraine days per month. Participants received rimegepant 75 mg every other day or placebo for 12 weeks.

The primary endpoint was the change from baseline in mean monthly migraine days during weeks 9 through 12. Rimegepant reduced monthly migraine days by 4.3 days versus 3.5 days for placebo, a statistically significant difference. Roughly 49% of participants on rimegepant achieved a 50% or greater reduction in monthly migraine days compared with 41% on placebo.

What the trial did not tell us about women specifically

About 87% of BHV3000-305 participants were women, which is consistent with migraine epidemiology. However, the trial did not pre-specify subgroup analyses by menstrual cycle phase, hormonal contraceptive use, or menopausal status. This is a real evidence gap. We know rimegepant works for women in aggregate, but we do not have RCT data showing whether women with menstrual migraine, PCOS-driven hormonal fluctuation, or perimenopausal estrogen volatility respond differently to every-other-day dosing than women without these conditions.

A practical clinical framework for the acute-to-prevention switch in women, based on the label, the BHV3000-305 data, and sex-specific migraine physiology:

| Trigger pattern | Life stage | Consider switching to every-other-day prevention when... | |---|---|---| | Menstrual migraine only | Reproductive years | Attacks occur >2 days/month or acute therapy fails repeatedly | | Hormonally driven + other triggers | Reproductive years / PCOS | Total migraine days >4/month OR medication-overuse risk | | Escalating frequency | Perimenopause | Any upward trend in migraine days as cycles become irregular | | Unpredictable attacks | Post-menopause | Frequency >4/month; rule out secondary causes first |

How sex-specific physiology changes the picture

Migraine is three times more common in women than in men, and that gap is almost entirely explained by reproductive hormones. Understanding where you sit in your hormonal life stage helps predict whether the every-other-day schedule will be enough, or whether you may need combination strategies.

Reproductive years and menstrual migraine

Estrogen withdrawal in the late luteal phase is the dominant trigger for menstrual migraine, which affects up to 60% of women with migraine. Because estrogen-withdrawal attacks tend to cluster on days -2 to +3 of the menstrual cycle, every-other-day rimegepant provides continuous CGRP receptor coverage through the vulnerable window, unlike purely acute dosing.

One option some clinicians use is to run the every-other-day schedule as a background preventive and allow the patient to also take a single rimegepant 75 mg tablet as an acute rescue on a non-scheduled day. The label permits this because acute and preventive dosing have the same formulation, and the prescribing information does not prohibit acute use on off-days, though the prescriber should review total tablet consumption per month.

PCOS

Women with PCOS often have irregular cycles, higher androgen exposure, and insulin resistance, all of which may independently influence migraine frequency. There is no rimegepant-specific RCT data in PCOS populations. Given the hormonal volatility, PCOS patients who also have migraine may need the preventive schedule rather than acute-only dosing, but this remains a clinical judgment call rather than a guideline recommendation.

Perimenopause

The perimenopausal years are frequently when women who managed migraine reasonably well during their reproductive years suddenly find acute medication no longer sufficient. Estrogen fluctuations in perimenopause are erratic and large, and migraine frequency can double or triple. The Menopause Society (formerly NAMS) recognizes migraine as a clinically significant concern in the menopausal transition and advises individualized headache management. Switching to every-other-day rimegepant during perimenopause is one rational strategy, particularly for women who cannot use estrogen-containing therapies due to aura.

Post-menopause

Migraine often improves after natural menopause because estrogen stabilizes at a low, consistent level. Women who still have frequent migraine after menopause should be evaluated for secondary headache causes before assuming primary migraine. For those with confirmed post-menopausal migraine at a frequency of more than four days per month, every-other-day rimegepant remains an option.

How to make the switch: practical steps

Making the switch from as-needed to every-other-day dosing does not require tapering your current schedule or any washout period. The steps below reflect the approved label and routine clinical practice.

Step 1: Confirm you meet the preventive threshold

Standard practice, supported by American Headache Society guidance, is to offer preventive therapy when a patient has four or more migraine days per month, when acute therapy is failing, or when medication-overuse headache is developing. Overuse is generally defined as using acute migraine treatments on 10 or more days per month for triptans, ergotamines, or combination analgesics, or 15 or more days per month for plain NSAIDs.

Step 2: Get a new or updated prescription

Your prescriber writes for rimegepant 75 mg every other day (preventive). Because the tablet is identical to the acute formulation, the only change is the prescribed frequency and the total quantity dispensed per month (approximately 15 tablets per 30-day fill).

Step 3: Pick a start day and stick to the schedule

Choose any day to start. Take one tablet that morning. Skip the next day. Take one tablet the following morning. Continue this pattern. A phone calendar reminder set every other day reduces missed doses, which matter more for a preventive than for an acute as-needed therapy.

Step 4: Continue to track headache days

Use a headache diary or app for at least 12 weeks before concluding whether prevention is working. The BHV3000-305 trial measured the primary endpoint at weeks 9 through 12, meaning the full preventive benefit may not be visible until you have been on every-other-day dosing for two to three months.

Step 5: Decide whether to keep an acute rescue plan

Some clinicians allow patients on every-other-day prevention to use a separate acute agent (such as a triptan) on breakthrough days. Others allow an additional rimegepant tablet on off-days. Discuss this explicitly with your prescriber so you have a clear plan before the next attack.

Who this is right for, and who should pause before switching

Good candidates for every-other-day rimegepant

• Women with four or more migraine days per month who have not responded adequately to acute treatment alone
• Women with menstrual migraine who want continuous CGRP blockade through the luteal phase
• Women in perimenopause with escalating attack frequency
• Women who cannot tolerate or have contraindications to older oral preventives (topiramate, valproate, amitriptyline, beta-blockers)
• Women who have already been prescribed rimegepant acutely and want to consolidate to one medication for both purposes

Women who should pause and discuss further

• Women who are pregnant, planning pregnancy, or breastfeeding (see the dedicated section below)
• Women with four or fewer migraine days per month who are managing well on acute therapy alone. Prevention adds cost and tablet burden without clear benefit at low frequency.
• Women with hepatic impairment. Rimegepant exposure is increased in severe hepatic impairment, and the label advises avoiding use in this population.
• Women currently taking strong CYP3A4 inhibitors or strong P-glycoprotein inhibitors. Co-administration is not recommended because rimegepant exposure roughly doubles.

Pregnancy, lactation, and contraception

This section is required reading if you are pregnant, trying to conceive, or breastfeeding. Rimegepant's safety profile in pregnancy is not established.

Pregnancy

The FDA label states that there are no adequate and well-controlled studies of rimegepant in pregnant women. Animal reproduction studies showed adverse developmental effects at exposures above the clinical dose, but animal data do not always predict human risk. Rimegepant should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. This is a clinical judgment your obstetric provider must make with you.

Migraine itself does not typically worsen in the first trimester and often improves by the second trimester in women with hormonal triggers, but attacks can persist or worsen, particularly in women with chronic migraine. If you are pregnant and need acute migraine treatment, ACOG recommends discussing acetaminophen as a first-line option for pain relief, with triptans considered if safer options fail, but rimegepant is not currently listed among first-choice options in pregnancy due to insufficient data.

Trying to conceive

If you are actively trying to become pregnant, discuss transitioning off rimegepant with your provider before conception occurs. Because onset of pregnancy is often not recognized until several weeks in, women with a realistic chance of pregnancy each cycle should have a clear plan in place, not one that requires waiting for a positive test.

Postpartum and lactation

The FDA label reports that rimegepant is present in human milk. There are no data on the effects of rimegepant on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered alongside the mother's clinical need for migraine prevention and the potential infant exposure. This is a shared decision with your provider. Women who had well-controlled migraine on rimegepant before pregnancy may face a difficult postpartum period without it, particularly given postpartum hormonal shifts that can trigger migraine.

Contraception requirement

Rimegepant is not classified as a known human teratogen requiring a formal Risk Evaluation and Mitigation Strategy (REMS) or mandatory contraception, unlike valproate or topiramate. However, given the absence of pregnancy safety data, women of reproductive age who are sexually active and not planning pregnancy should use reliable contraception while on every-other-day rimegepant. This is a practical precaution, not a regulatory mandate.

Comparing every-other-day rimegepant to other preventive options

Every-other-day rimegepant is not the only CGRP-pathway preventive for women. The comparison below focuses on features most relevant to women's health decisions.

| Preventive | Mechanism | Dosing | Pregnancy concern | Teratogen | |---|---|---|---|---| | Rimegepant 75 mg EOD | CGRP receptor antagonist (oral) | Every other day | No adequate human data | No formal REMS | | Erenumab (Aimovig) | Anti-CGRP receptor mAb (injection) | Monthly SC | No adequate human data | No formal REMS | | Fremanezumab (Ajovy) | Anti-CGRP mAb (injection) | Monthly or quarterly SC | No adequate human data | No formal REMS | | Topiramate (Topamax) | Multiple mechanisms (oral) | Daily | Known teratogen; PREA / REMS required; associated with cleft palate | Yes, REMS for women of childbearing potential | | Valproate (Depakote) | Anticonvulsant (oral) | Daily | Highly teratogenic; REMS program; associated with neural tube defects | Yes, mandatory REMS | | Amitriptyline | Tricyclic antidepressant (oral) | Daily | Limited data; not preferred in pregnancy | No |

For women with PCOS or insulin resistance who want to avoid topiramate's metabolic effects, or for any woman who cannot tolerate the older oral preventives, every-other-day rimegepant offers a meaningful alternative without the teratogen risk of topiramate or valproate.

Monitoring and what to expect in the first 12 weeks

Most patients do not feel an immediate reduction in migraine frequency when starting every-other-day rimegepant. The effect builds over weeks. Based on the BHV3000-305 trial data, the separation from placebo becomes clinically meaningful around weeks 9 to 12.

Side effects to track

The most common adverse events reported in BHV3000-305 were nausea (2.7% rimegepant versus 0.8% placebo) and urinary tract infection (1.9% versus 1.4%). No new safety signals emerged at every-other-day dosing compared to acute use. The FDA label does not list any sex-specific adverse effects that differ between women and men.

When to call your provider before 12 weeks

Contact your prescriber if:

• You develop signs of a hypersensitivity reaction (rash, facial swelling, difficulty breathing). Hypersensitivity reactions have been reported post-marketing, some serious.
• You become pregnant.
• Your migraine frequency worsens rather than improves after four to six weeks on the schedule.
• You start a new medication that may interact with rimegepant (especially antifungals like ketoconazole or antiretrovirals that are strong CYP3A4 inhibitors).

Reassessing at week 12

At the 12-week mark, compare your headache diary to baseline. A 50% reduction in monthly migraine days is the standard benchmark for "response" to a preventive, drawn from International Headache Society guidelines on clinical trial endpoints. If you have not reached that threshold, your provider may discuss adding or switching to a different class of preventive rather than continuing every-other-day rimegepant alone.

A note on cost and insurance

Rimegepant (Nurtec ODT) is a branded medication with no generic currently available. Insurance coverage for the preventive every-other-day indication may differ from coverage for acute use, even though the tablet is identical. Some plans require a prior authorization specifically for the preventive indication. Check with your pharmacy benefits manager before assuming your current acute coverage extends to the every-other-day schedule. The manufacturer (Pfizer/Biohaven) has a copay assistance program for commercially insured patients.